Atopic Dermatitis
A prospective observational study of patients receiving Dupixent for Atopic Dermatitis.
ENROLLMENT CLOSED
https://clinicaltrials.gov/ct2...
A phase 3 randomized, placebo-controlled, double-blinded study to evaluate Upadacitinib in adolescents and adult subjects with moderate to severe Atopic Dermatitis.
ENROLLMENT CLOSED
https://clinicaltrials.gov/ct2...
A phase 3B multi center, randomized, double-blind, double-dummy, active controlled study comparing the safety Upadacitinib to Dupilumab in adult subjects with moderate to sever Atopic Dermatitis.
ENROLLMENT OPEN
https://clinicaltrials.gov/ct2…
Psoriasis
A multicenter, open-label, randomized study to assess the pharmacokinetics, safety, and efficacy of two doses of Bimekizumab in adolescent study participants with moderate to severe plaque psoriasis.
ENROLLMENT CLOSED
https://www.clinicaltrials.gov...
A Phase 3B, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to Secukinumab or Ixekizumab and are switched to Risankizumab.
ENROLLMENT CLOSED
https://clinicaltrials.gov/ct2...
For more information contact Katy Martz at 660-956-7078 or email [email protected] .
